Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma
with Acquired High-level HER2 Amplification: A Case Report

Trastuzumab deruxtecan is a newly developed antibody-drug conjugate (ADC) designed to overcome human epidermal growth factor receptor 2 (HER2) aberrations. Studies have confirmed that Trastuzumab deruxtecan yields promising efficacy with a manageable safety profile in previously treated non-small ce...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Xiaoxiao GE, Hefeng CHEN, Shaohua CUI
التنسيق:	Artigo
اللغة:	Chinês
منشور في:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2026-03-01
سلاسل:	Chinese Journal of Lung Cancer
الموضوعات:	lung neoplasms trastuzumab deruxtecan her2 amplification acquired resistance case report
الوصول للمادة أونلاين:	http://dx.doi.org/10.3779/j.issn.1009-3419.2026.104.01
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!